Martin Cowie at AstraZeneca elaborates on the urgent need for faster diagnoses in the field of heart failure.

As the life sciences become increasingly aware of a lack in diversity, how can we improve this in genomics research?

How are corneal transplants advancing in the field of ophthalmology?

How is primary biliary cholangitis (PBC) currently affecting patients; and, more importantly, what hopes does PBC Awareness Month bring for new treatment options?

How can the combined power of multidisciplinary teams and precision medicine be harnessed for people living with bladder cancer?

Oral peptides are becoming an attractive drug candidate due to their efficacy and potency. How are parenteral drug products impacting the distribution of this new candidate?

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments

Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments

Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

Ahead of clinical trials day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices to accelerate rare disease innovation